Tag: KDC-MN-207

  • Venlafaxine

    Serotonin-norepinephrine reuptake inhibitor

    A bicyclic SNRI with dose-dependent transporter selectivity; the prototype dual-action antidepressant.

    Abstract

    Venlafaxine ((R/S)-1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexan-1-ol; CAS 93413-69-5; molecular formula C17H27NO2; molecular weight 277.40) is a bicyclic phenethylamine SNRI developed at Wyeth and approved by the FDA in 1993 under the trade name Effexor. The active metabolite O-desmethylvenlafaxine (desvenlafaxine, marketed separately as Pristiq) carries comparable transporter activity and contributes substantially to the steady-state effect. Plasma half-life of the parent compound is approximately 5 hours; the metabolite half-life is approximately 11 hours. Metabolism is via CYP2D6 (primary) and CYP3A4 (secondary). The compound exhibits a pronounced discontinuation syndrome, attributed to the short half-life and combined serotonergic-noradrenergic withdrawal. Used as the reference SNRI in mechanism studies and as a positive control in dual-action antidepressant pharmacology research.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.